Conatus Pharmaceuticals (NASDAQ: CNAT) cirrhosis drug data looks interesting, said RBC analyst Michael J. Yee, though Phase II study of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE